Vuoristo MS - Search Results

1

Intermittent interferon and polychemotherapy in metastatic melanoma.

Vuoristo MS, Gröhn P, Kellokumpu-Lehtinen P, Kumpulainen E, Turunen M, Korpela M, Joensuu H, Tiusanen K, Nevantaus A. Vuoristo MS, et al. J Cancer Res Clin Oncol. 1995;121(3):175-80. doi: 10.1007/BF01198100. J Cancer Res Clin Oncol. 1995. PMID: 7536196 Clinical Trial.

2

A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine.

Gröhn P, Kumpulainen E, Nuortio L, Hakala T, Vuoristo MS, Korpela M, Heikkinen M, Salmi R, Jakobsson M, Numminen S. Gröhn P, et al. Among authors: vuoristo ms. Eur J Cancer. 1992;28(2-3):441-3. doi: 10.1016/s0959-8049(05)80072-3. Eur J Cancer. 1992. PMID: 1591060 Clinical Trial.

3

A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma.

Vuoristo M, Jantunen I, Pyrhönen S, Muhonen T, Kellokumpu-Lehtinen P. Vuoristo M, et al. Eur J Cancer. 1994;30A(4):530-2. doi: 10.1016/0959-8049(94)90433-2. Eur J Cancer. 1994. PMID: 8018415 Clinical Trial.

4

Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.

Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, Soppi E. Vuoristo MS, et al. Immunopharmacol Immunotoxicol. 1996 Aug;18(3):337-54. doi: 10.3109/08923979609052740. Immunopharmacol Immunotoxicol. 1996. PMID: 8872489

5

Complete responses and survival after polychemotherapy plus interferon-alpha for patients with metastatic melanoma.

Vuoristo MS. Vuoristo MS. Melanoma Res. 1996 Aug;6(4):331-6. doi: 10.1097/00008390-199608000-00009. Melanoma Res. 1996. PMID: 8873054 Clinical Trial.

6

The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.

Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E. Vuoristo MS, et al. Melanoma Res. 2000 Jun;10(3):237-41. Melanoma Res. 2000. PMID: 10890377 Clinical Trial.

7

Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma.

Vuoristo MS, Kellokumpu-Lehtinen P, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E, Laine S. Vuoristo MS, et al. Acta Oncol. 2000;39(7):877-9. doi: 10.1080/028418600750063659. Acta Oncol. 2000. PMID: 11145448

8

Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma.

Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E, Kellokumpu-Lehtinen P. Vuoristo MS, et al. Eur J Cancer. 2001 Sep;37(13):1629-34. doi: 10.1016/s0959-8049(01)00192-7. Eur J Cancer. 2001. PMID: 11527688

9

High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.

Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM, Pyrhönen S. Nikkola J, et al. Among authors: vuoristo ms. Clin Cancer Res. 2005 Jul 15;11(14):5158-66. doi: 10.1158/1078-0432.CCR-04-2478. Clin Cancer Res. 2005. PMID: 16033831

10

Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.

Vuoristo MS, Hahka-Kemppinen M, Parvinen LM, Pyrhönen S, Seppä H, Korpela M, Kellokumpu-Lehtinen P. Vuoristo MS, et al. Melanoma Res. 2005 Aug;15(4):291-6. doi: 10.1097/00008390-200508000-00010. Melanoma Res. 2005. PMID: 16034308 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters